Adalimumab induction therapy for Crohn disease previously treated with infliximab - A randomized trial
Sandborn, William J × Rutgeerts, Paul Enns, Robert Hanauer, Stephen B Colombel, Jean-Frederic Panaccione, Remo D'Haens, Geert Liu, Junhu Rosenfeld, Marie R Kent, Jeffrey D Pollack, Paul F #
American College of Physicians
Annals of Internal Medicine vol:146 issue:12 pages:829-838
Background: Adalimumab, a fully human tumor necrosis factor (TNF) antagonist, is an effective treatment for patients with Crohn disease who are naive to the chimeric TNF antagonist, infliximab. No anti-TNF agent has been evaluated prospectively in patients with Crohn disease who had responded to another anti-TNF agent and then lost that response or were intolerant of the agent.